Supernus Pharmaceuticals Inc SUPN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $32.15
- Day Range
- $31.91–32.19
- 52-Week Range
- $22.07–35.42
- Bid/Ask
- $31.84 / $32.13
- Market Cap
- $1.76 Bil
- Volume/Avg
- 6,244 / 438,985
Key Statistics
- Price/Earnings (Normalized)
- 110.53
- Price/Sales
- 2.79
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. The Company's diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Core
- Total Number of Employees
- 652
- Website
- https://www.supernus.com
Comparables
Valuation
|
Metric
|
SUPN
|
AVIR
|
ELYM
|
|---|---|---|---|
Price/Earnings (Normalized) | 110.53 | — | — |
Price/Book Value | 1.85 | 0.60 | 1.54 |
Price/Sales | 2.79 | — | — |
Price/Cash Flow | 15.69 | — | — |
Price/Earnings
SUPN
AVIR
ELYM
Financial Strength
|
Metric
|
SUPN
|
AVIR
|
ELYM
|
|---|---|---|---|
Quick Ratio | 1.62 | 18.87 | 59.65 |
Current Ratio | 1.91 | 19.02 | 60.41 |
Interest Coverage | — | — | — |
Quick Ratio
SUPN
AVIR
ELYM
Profitability
|
Metric
|
SUPN
|
AVIR
|
ELYM
|
|---|---|---|---|
Return on Assets (Normalized) | 2.90% | −23.62% | −45.38% |
Return on Equity (Normalized) | 4.05% | −25.11% | −46.50% |
Return on Invested Capital (Normalized) | 2.99% | −29.21% | −46.38% |
Return on Assets
SUPN
AVIR
ELYM
Drug Manufacturers - Specialty & Generic Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Zoetis Inc Class A
ZTS
| Dvjxsnhwc | Htpzm | $87.2 Bil | |||
| Merck KGaA ADR
MKKGY
| Zksyrtzrg | Wrtvfxm | $75.7 Bil | |||
| Haleon PLC ADR
HLN
| Hyzscwct | Kktl | $47.3 Bil | |||
| Teva Pharmaceutical Industries Ltd ADR
TEVA
| Yhdjjnglx | Jxptl | $20.0 Bil | |||
| Viatris Inc
VTRS
| Dymrfxbq | Ykbv | $13.7 Bil | |||
| Dr Reddy's Laboratories Ltd ADR
RDY
| Ldkzfnl | Jlpt | $13.4 Bil | |||
| Catalent Inc
CTLT
| Dmvglfwc | Zsvtvbc | $11.0 Bil | |||
| Prestige Consumer Healthcare Inc
PBH
| Vlrnwhbqp | Tnjnm | $3.5 Bil | |||
| Perrigo Co PLC
PRGO
| Pyyxtzq | Gwccw | $3.4 Bil | |||
| Green Thumb Industries Inc
GTBIF
| Bpvqvdwgr | Vbxr | $2.4 Bil |
United States